Attached files
| file | filename |
|---|---|
| EX-10.2 - FORM OF $250,0000 PROMISSORY NOTE AMENDMENT - THERALINK TECHNOLOGIES, INC. | exhibit10-2.htm |
| EX-10.1 - FORM OF $50,000 PROMISSORY NOTE AMENDMENT - THERALINK TECHNOLOGIES, INC. | exhibit10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 25, 2012
PEDIATRX INC.
(Exact name
of registrant as specified in its charter)
| Nevada | 000-52218 | 20-2590810 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
| incorporation) |
| 90 Fairmount Road West, Califon, NJ | 07830 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (908) 975-0753
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e -4(c))
Item 1.01 Entry into a Material Definitive Agreement.
Please see the disclosure under Item 2.03 of this current report on Form 8-K.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Effective July 25, 2012, we entered into two amendments of two unsecured promissory notes. The first of the two promissory notes, originally dated June 15, 2009 and previously amended on May 23, 2011, in the principal amount of $50,000 with simple interest at a rate of 5% per annum, was amended to a) extend the maturity date of the note from August 15, 2012 until December 31, 2012 and to b) increase the interest rate from 5% to 12% per annum, such new rate to be applied from the amendment date forward. The second of the two promissory notes dated May 6, 2011, and previously amended on May 23, 2011 and April 19, 2012, in the principal amount of $250,000 with simple interest at a rate of 5% per annum, was amended a) to extend the maturity date of the note from August 15, 2012 until December 31, 2012 and tob) increase the interest rate from 5% to 12% per annum, such new rate to be applied from the amendment date forward.
All other terms of the promissory note remain the same.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 10.1 | Form of $50,000 Promissory Note Amendment dated July 25, 2012 |
| 10.2 | Form of $250,0000 Promissory Note Amendment dated July 25, 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PEDIATRX INC.
| /s/ Cameron Durrant |
| Cameron Durrant |
| President, Chief Executive Officer and Director |
| Date: July 31, 2012 |